Skip to main content
Professionals

Please explore the resources below and the the "More Filters" button below to find specific resources in your search. The documents in this section include Guidelines, Publications, Presentations, Videos and Papers for specific Conditions and Procedures.

Find a guideline or consensus statement Click Here
Audience




Type
















Conditions


































Procedures












Other










Results in 'Consensus Statements and Guidelines'

FIT in patients with signs or symptoms of suspected CRC: A joint guideline from ACPGBI and BSG

1 June 2022
Consensus Statements and Guidelines

Authors (Guideline development group (GDG)) Kevin J Monahan / Michael M. Davies (Co-chairs, and lead authors). Co-authors: Muti Abulafi, Ayan Banerjea, Brian Nicholson, Ramesh Arasaradnam, Neil Barker, Sally Benton, Richard Booth, David Burling, Rachel Carten, Nigel D’Souza, James East, Jos Kleijnen, Michael Machesney, Maria Pettman, Jenny Pipe, Lance Saker, Linda Sharp, James Stephenson, Robert Steele.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment (2021)

2 May 2022
Consensus Statements and Guidelines

This is the second of a series of two articles reporting the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis [UC]. The first article is focused on medical management, and the present article addresses medical treatment of acute severe ulcerative colitis [ASUC] and surgical management of medically refractory UC patients, including preoperative optimisation, surgical strategies, and technical issues. The article provides advice for a variety of common clinical and surgical conditions. Together, the articles represent an update of the evidence-based recommendations of the ECCO for UC.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment (2021)

2 May 2022
Consensus Statements and Guidelines

Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic inflammation extending to a variable extent from the rectum. Care of the patient with UC requires appropriate input from across the multiprofessional team. These guidelines summarise the recommended medical treatment for adults with UC. Other ECCO guidelines consider the approach to UC diagnosis and monitoring,1–3 nursing care,4 management of disease complications,5–7 risk of infection,8 and technical aspects of surgery.9 This document was prepared as part of a process that also led to the publication of a related guideline with recommendations on the surgical care of the patients with UC and on the medical aspects of the management of the patient hospitalised with severe UC. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

BAPEN-BSG position statements on intestinal failure

2 May 2022
Consensus Statements and Guidelines

“The British Intestinal Failure Alliance (BIFA) is a multi-professional special interest group within the British Association for Parenteral and Enteral Nutrition (BAPEN). It focuses on temporary/reversible intestinal failure (IF) (Type 2 IF) and patients needing home parenteral support (nutrition and/or fluid) (Type 3 IF). The guidelines/recommendations and the position statements have all been written by the named authors and revised by the BIFA committee and BAPEN council. They aim to help staff working with patients with IF and those needing parenteral support.”

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease (2021)

2 May 2022
Consensus Statements and Guidelines

The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease [IBD] in recent decades. With such immunosuppression, the potential for opportunistic infection is a key safety concern. Opportunistic infections pose particular problems for the clinician; they are potentially serious, often difficult to recognise, associated with appreciable morbidity or mortality, and are challenging to treat effectively. The first guideline on opportunistic infections was published in 20091 followed by an update in 2014.2 New evidence in this field and in vaccination strategies for immunosuppressed IBD patients led the European Crohn’s and Colitis Organization [ECCO] to update the previous consensus on opportunistic infections in IBD. The current document is focused on viral, mycobacterial, bacterial, fungal, and parasitic infections and on vaccination strategies for immunosuppressed IBD patients. The target audience includes IBD specialists, gastroenterologists, surgeons, and paediatricians.

ECCO guidelines on therapeutics disease in Crohn’s disease: Surgical treatment (2019)

2 May 2022
Consensus Statements and Guidelines

This article is the second in a series of two publications relating to the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn’s disease and an update of previous guidelines.

ECCO guidelines on therapeutics disease in Crohn’s disease: Medical treatment (2019)

2 May 2022
Consensus Statements and Guidelines

Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability.1 CD can affect individuals of any age, from children to the elderly,2,3 and may cause significant morbidity and impact on quality of life. Up to one-third of patients present with complicated behaviour [strictures, fistula, or abscesses] at diagnosis.4 Most patients over time will develop a complication, with roughly 50% of patients requiring surgery within 10 years of diagnosis.5–7 As the precise aetiology of CD remains unknown, a curative therapy is not yet available.8 Several agents are available for the medical treatment of CD. Medical agents include mesalazine [5-ASA], locally active steroids [such as budesonide], systemic steroids, thiopurines such as azathioprine [AZA] and mercaptopurine [MP], methotrexate [MTX], and biologic therapies (such as anti-tumour necrosis factor [TNF], anti-integrins, and anti-interleukin [IL] 12/23].

BSG-ACPGBI guidelines for the management of large non-pedunculated colorectal polyps

17 August 2021
Consensus Statements and Guidelines

These guidelines provide an evidence-based framework for the management of patients with large nonpedunculated colorectal polyps.

BSG/ACPGBI/PHE Post-polypectomy and post-colorectal cancer resection surveillance guidelines

17 August 2021
ACPGBI Publications
Good Practice
Consensus Statements and Guidelines

These guidelines have been reviewed and endorsed by BSG CSSC and ACPGBI in 2020.

Joint ACPGBI and The Duke's Club statement on colonoscopy training

17 August 2021
ACPGBI Publications
Consensus Statements and Guidelines
Presentations, Videos & Papers

A publication by the ACPGBI Colonoscopy Subcommittee